Key Takeaways
- • Isomorphic Labs captured the largest H1 2025 biopharma venture raise at $600 million in March, leveraging AI-designed drug discovery technology from its Google DeepMind parent with a current valuation of $1.8 billion and partnerships worth nearly $3 billion from Eli Lilly and Novartis combined.
- • Biopharma venture capital fundraising continues a four-quarter downward trend, with quarterly volume holding steady at $8–$9 billion despite falling deal counts and total amounts raised in Q2 2025, signaling structural headwinds across the sector.
- • Obesity and metabolic disease dominate H1 2025 funding priorities, with companies like Verdiva Bio ($411 million) competing against larger pharma incumbents (Novo Nordisk, Eli Lilly) in next-generation therapeutic development.
- • AI-driven drug discovery emerges as the primary magnet for institutional capital in early 2025, with multiple unicorn-status biotech firms built exclusively on AI platforms attracting mega-rounds despite the broader fundraising slowdown.
- • Series A and Series B funding rounds are ticking upward according to BioPulse data, suggesting institutional investors are shifting capital allocation toward earlier-stage companies despite overall VC contraction in the biopharma ecosystem.
Summary
Biopharma venture capital fundraising entered 2025 under structural pressure, with data from Citeline and PitchBook documenting a four-quarter declining trend that reverses the pandemic-era capital flood of 2021. Despite this headwind, institutional capital continues to concentrate in high-conviction themes, with mega-rounds flowing to AI-centric platforms and obesity-focused therapeutics.
Isomorphic Labs, a spinout from Google's DeepMind division, led H1 2025 fundraising by securing $600 million in March 2025 for AI-designed drug discovery. The company, now valued at approximately $1.8 billion, has secured landmark partnerships with Eli Lilly and Novartis totaling nearly $3 billion in combined biobucks, despite having no published pipeline or disclosed disease targets. Management expects to initiate clinical trials for newly discovered molecules by year-end 2025. Isomorphic represents one of a handful of biotech unicorns built exclusively on AI platforms, reflecting investor conviction in computational drug discovery as a structural shift in R&D productivity.
Verdiva Bio ranked second with a $411 million raise targeting obesity and metabolic disease, positioning itself in a crowded therapeutic space where established pharma giants like Novo Nordisk and Eli Lilly have dominated with blockbuster GLP-1 agonists. The clustering of capital into obesity therapeutics signals investor appetite for next-generation approaches as market saturation concerns emerge around existing franchise leaders.
The broader fundraising environment remained constrained, with quarterly venture volumes holding steady at $8–$9 billion across the past five quarters despite declining deal counts and total capital deployed in Q2 2025. However, early-stage funding dynamics diverged from this trend, with Series A and Series B rounds ticking upward according to BioPulse data, suggesting a bifurcated market where institutional capital preferentially backs either established platforms with de-risked technology (Isomorphic) or early-stage companies with perceived innovation advantages over legacy approaches.
Isomorphic Labs, a spinout from Google's DeepMind division, led H1 2025 fundraising by securing $600 million in March 2025 for AI-designed drug discovery. The company, now valued at approximately $1.8 billion, has secured landmark partnerships with Eli Lilly and Novartis totaling nearly $3 billion in combined biobucks, despite having no published pipeline or disclosed disease targets. Management expects to initiate clinical trials for newly discovered molecules by year-end 2025. Isomorphic represents one of a handful of biotech unicorns built exclusively on AI platforms, reflecting investor conviction in computational drug discovery as a structural shift in R&D productivity.
Verdiva Bio ranked second with a $411 million raise targeting obesity and metabolic disease, positioning itself in a crowded therapeutic space where established pharma giants like Novo Nordisk and Eli Lilly have dominated with blockbuster GLP-1 agonists. The clustering of capital into obesity therapeutics signals investor appetite for next-generation approaches as market saturation concerns emerge around existing franchise leaders.
The broader fundraising environment remained constrained, with quarterly venture volumes holding steady at $8–$9 billion across the past five quarters despite declining deal counts and total capital deployed in Q2 2025. However, early-stage funding dynamics diverged from this trend, with Series A and Series B rounds ticking upward according to BioPulse data, suggesting a bifurcated market where institutional capital preferentially backs either established platforms with de-risked technology (Isomorphic) or early-stage companies with perceived innovation advantages over legacy approaches.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.